Stockscreener 앱 받기
2.42
1.26%
0.03
InspireMD Inc. 주식(NSPR)의 최신 뉴스
Is InspireMD Inc. showing insider buyingExtreme Return Watchlist - sisaissue.com
InspireMD signals robust U.S. CGuard Prime launch progress and expands clinical pipeline following $58M capital infusion - MSN
InspireMD, Inc. (NASDAQ:NSPR) Q2 2025 Earnings Call Transcript - Insider Monkey
InspireMD Q2 Earnings: Revenue Down, CEO Confident in Future Growth - AInvest
InspireMD Reports Q2 2025 Financial Results and Milestones Amid FDA Approval and US Launch of CGuard Prime Carotid Stent System - AInvest
InspireMD Inc (NSPR) Q2 2025 Earnings Call Highlights: Strategic US Launch Amid Financial Challenges - Investing.com Canada
InspireMD Inc. Navigates Trade Policy Risks with U.S. Manufacturing Plans - TipRanks
InspireMD Inc. Reports Q2 2025 Earnings and Regulatory Milestones - TipRanks
InspireMD’s Earnings Call: FDA Approval and Financial Challenges - TipRanks
InspireMD reports Q2 EPS (26c) vs (22c) last year - TipRanks
InspireMD's Strategic U.S. Expansion and Product Launch Momentum: A Balancing Act of Optimism and Caution - AInvest
InspireMD's Strategic Capital Raise and Clinical Innovation Position It as a High-Conviction Growth Play in the $5B+ U.S. Coronary Stent Market - AInvest
InspireMD's Q2 2025: Key Contradictions in FDA Approval, Product Launches, and U.S. Market Strategy - AInvest
InspireMD Experiences Robust US Launch Progress and Expands Clinical Pipeline Following $58M Investment - AInvest
InspireMD shares fall 1.50% intraday despite Q2 revenue beating estimates. - AInvest
Earnings call transcript: InspireMD Q2 2025 misses EPS forecast, stock rises - Investing.com Canada
Earnings call transcript: InspireMD Q2 2025 misses EPS forecast, stock rises By Investing.com - Investing.com South Africa
InspireMD earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
InspireMD Reports Q2 2025 Financial Results and Milestones - TipRanks
InspireMD's Q2 Results: Revenue Misses Expectations, GAAP EPS at -$0.26 - AInvest
InspireMD Announces Second Quarter 2025 Financial Results and Investor Conference Call Details - Quiver Quantitative
InspireMD gets FDA approval for CGuard Prime carotid stent system. - AInvest
InspireMD Reports Second Quarter 2025 Financial Results - GlobeNewswire
InspireMD Secures FDA Approval for Revolutionary Stroke Prevention Stent, Raises $58M for US Launch - Stock Titan
InspireMD Inc. Outperforms Peers on Volume MetricsTrade Ready Stock Watch for Short Term Published - metal.it
InspireMD, Inc. SEC 10-Q Report - TradingView
InspireMD's Q2 2025 Earnings and Strategic Momentum: A Path to Profitability Amid Uncertainty - AInvest
Does InspireMD Inc. stock perform well during market downturnsUnlock daily stock market insights for success - Jammu Links News
What makes InspireMD Inc. stock price move sharplyInvest confidently with daily market forecasts - Jammu Links News
What analysts say about InspireMD Inc. stockHigh-impact stock picks - Jammu Links News
What is the dividend policy of InspireMD Inc. stockUnlock powerful market analysis and alerts - Jammu Links News
How volatile is InspireMD Inc. stock compared to the marketSuperior profit margins - Jammu Links News
What is InspireMD Inc. company’s growth strategyOutstanding yields - Jammu Links News
Is it the right time to buy InspireMD Inc. stockMaximize returns with strategic trading plans - Jammu Links News
How strong is InspireMD Inc. company’s balance sheetFree Predictions - Jammu Links News
InspireMD's Turnaround: Sustainable Progress or Fleeting Optimism? - AInvest
Investors in InspireMD (NASDAQ:NSPR) from five years ago are still down 60%, even after 11% gain this past week - Yahoo Finance
Is a relief rally coming for InspireMD Inc. holdersFree Strong Buy With Technical Confidence - Newser
Why InspireMD Inc. stock attracts strong analyst attentionAlpha Generation Strategy with Low Volatility - Newser
Strategies to average down on InspireMD Inc.Real Chart Based Opportunity Identification - Newser
When is InspireMD Inc. stock expected to show significant growthAccess high-quality stock research instantly - Jammu Links News
What earnings revisions data tells us about InspireMD Inc.Technical Chart Summary for Momentum Stocks - Newser
What is the risk reward ratio of investing in InspireMD Inc. stockFree Market Dynamics Reports - Jammu Links News
How does InspireMD Inc. compare to its industry peersBuild a portfolio with strong long-term growth - Jammu Links News
Is InspireMD Inc. a growth stock or a value stockBreakout profit opportunities - Jammu Links News
What are InspireMD Inc. company’s key revenue driversSignificant capital appreciation - Jammu Links News
How many analysts rate InspireMD Inc. as a “Buy”Discover stocks with superior performance - Jammu Links News
InspireMD Inc Director Gary Roubin Makes Substantial Purchase of 41,322 Shares - AInvest
Is InspireMD Inc. stock bottoming outBull Market Summary and Recovery Outlook - Newser
Is InspireMD Inc. still worth holding after the dipFree Exit Ready Momentum Stock Watchlist - Newser
Published on: 2025-08-01 19:28:21 - Newser
Even after rising 14% this past week, InspireMD (NASDAQ:NSPR) shareholders are still down 59% over the past five years - simplywall.st
InspireMD raises $58M through combined financings; shares up - MSN
InspireMD Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
NSPR: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
What MACD signals say about InspireMD Inc.Free Community Shared Smart Money Signals - Newser
What machine learning models say about InspireMD Inc.Trend Reversal Probability Forecast Update - Newser
InspireMD outlines Q3 2025 FDA approval target for CGuard Prime - MSN
1.17%
자본화:
|
볼륨(24시간):